-
Fudan Zhangjiang: Taizhou Fudan Zhangjiang obtained the registration certificate of parecoxib sodium for injection
Time of Update: 2021-07-23
On February 25, Fudan Zhangjiang announced that the company’s wholly-owned subsidiary, Taizhou Fudan Zhangjiang, recently received the "Drug Registration Certificate" for parecoxib sodium for injection approved and issued by the State Food and Drug Administration .
-
The first wave of salary adjustments and employee optimization plans for pharmaceutical companies in 2021 are exposed!
Time of Update: 2021-07-23
It is reported that in January 2021, the French pharmaceutical giant Sanofi announced a layoff plan-the company will lay off 400 employees in the R&D department in France in the next three years.
-
Kelun Pharmaceutical: Metronidazole and Sodium Chloride Injection, Fat Emulsion Injection (C14~24) Review
Time of Update: 2021-07-23
Fat emulsion injection (C14~24) passed the consistency evaluation and obtained the approval notice of drug supplement application, which is mainly used for parenteral nutrition to supplement energy and essential fatty acids .
-
Junshi Biotech and AstraZeneca announce a commercialization strategic cooperation on triprolizumab
Time of Update: 2021-07-23
Junshi Biotechnology and AstraZeneca will continue to explore overseas business cooperation including emerging markets, and actively explore the possibility of expanding the depth and breadth of future cooperation on the basis of existing cooperation, and work together to create multi-pipeline cooperation between multinational pharmaceutical companies and local pharmaceutical companies It is a model for jointly promoting Chinese local innovative drugs to go abroad and benefit patients all over the world .
-
Innovent announces that the Phase I clinical study of anti-CD47/PD-L1 bispecific antibody has completed the first foreign patient administration
Time of Update: 2021-07-23
Cinda Biopharmaceuticals, a biopharmaceutical company dedicated to the development, production and sales of innovative drugs for the treatment of tumors, autoimmune, metabolic diseases and other major diseases, today announced its potential first anti-CD47/PD-L1 bispecific antibody (R&D code: IBI322) Phase I clinical study completed the first foreign patient drug administration .
-
The first batch of Wuhan-produced inactivated vaccines for the new crown is officially launched, and the annual output can reach 100 million doses
Time of Update: 2021-07-23
Wuhan Institute of Biological Products has built a biosafety workshop for the new crown inactivated vaccine.
It is understood that since July 16, 2020, China Bio-Wuhan has carried out the "New Coronary Inactivated Vaccine Phase III Clinical Trial" in many countries including the United Arab Emirates.
-
Allergan Aesthetics VOLUX Real World Data Research Project Achieves Phased Results
Time of Update: 2021-07-23
In December 2019, Allergan Aesthetics VOLUX® was approved by the Hainan Provincial Drug Administration and the Hainan Provincial Health Commission as a clinically urgently needed medical device in the advanced area of Boao Lecheng, and the team of Professor Li Qingfeng of Orthopedic Surgery of Shanghai Ninth Hospital completed the completion in Boao Super Hospital This is the first domestic injection to improve chin and maxillofacial volume .
-
Qiyu Biological Bispecific Antibody Q-1802 Obtained IND Approval in the United States
Time of Update: 2021-07-23
It has independent intellectual property rights and can simultaneously target PD-L1 and Claudin 18.
On the one hand, Q-1802 can kill tumors through effector cells mediated by Claudin 18.
-
The main contents of the "Blue Book of Health Insights on Patients with Multiple Sclerosis in China" released in Beijing
Time of Update: 2021-07-23
On the eve of the International Rare Disease Day on February 28, in order to understand the real treatment data of patients with multiple sclerosis and the status of standardized treatment of patient
-
Pfizer, Novartis, Sanofi, Takeda, Teva and many other rare disease new drugs have been listed in China and have been included in medical insurance
Time of Update: 2021-07-23
February 28, International Rare Disease Day . In recent years, China has introduced a series of favorable policies to bring good news to nearly 20 million patients with rare diseases in China. Dom
-
Haisco: Signed a cooperation agreement for olanzapine transdermal patch
Time of Update: 2021-07-23
Starton awarded Haisco with its research on a weekly olanzapine transdermal drug delivery system, a product intended to be used for nausea and vomiting caused by tumor chemotherapy STAR-OLZ has the exclusive right to develop, register and commercialize STAR-OLZ in mainland China .
-
Suqiao Biotech's partner Cinda Biotech's new crown antibody project was approved by the U.S. FDA IND
Time of Update: 2021-07-23
Warm congratulations on this project entering a new stage, and we also look forward to continuing to provide high quality for Cinda Biologics and other innovative biopharmaceutical companies And fast CMC service .
-
Nuocheng Jianhua's new TYK2 inhibitor ICP-332 new drug research application was accepted by the State Food and Drug Administration
Time of Update: 2021-07-23
On February 26, 2021, the biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) announced that the company's new tyrosine kinase 2 (Tyrosine Kinase 2, TYK2) inhibitor ICP-332 new drug research ( IND) application was accepted by the National Medical Products Administration (NMPA) .
-
Nuocheng Jianhua appoints Dr. Xiangyang Zhang as Chief Medical Officer
Time of Update: 2021-07-23
Xiangyang Zhang, who has extensive clinical and new drug development experience in the field of biomedicine, as the chief medical officer and co-founder of Nuocheng Jianhua , Chairman and CEO Dr.
Zhang Xiangyang's office in the United States further demonstrates Nuocheng Jianhua's commitment to global development .
-
Pfizer Biologics Etanercept Enters the National Medical Insurance List
Time of Update: 2021-07-23
In addition, the Sichuan Provincial Medical Security Bureau and Sichuan Provincial Department of Human Resources and Social Security also issued the "Notice on Issues Concerning the Implementation of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" on February 5.
-
Fuan Pharmaceutical's Esomeprazole Sodium for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-07-23
On March 1, Fuan Pharmaceutical issued an announcement stating that its subsidiary, Hubei People’s Pharmaceutical, had recently received a drug supplement application approval notice issued by NMPA,
-
Hebo Medicine's new generation of anti-CTLA-4 antibody HBM4003 has made new progress
Time of Update: 2021-07-23
Hebo Pharmaceutical announced today that the National Medical Products Administration (NMPA) approved its research product anti-CTLA-4 fully human monoclonal heavy chain antibody HBM4003 and PD-1 antibody/chemotherapy for the treatment of advanced non-small cell lung cancer and other solid tumors Patient's clinical trial application .
-
Deck Pharmaceuticals (6996.HK) was included in nine benchmark and thematic indexes including the Hang Seng Composite Index
Time of Update: 2021-07-23
The Hang Seng Southbound Stock Connect Index reflects the overall performance of Hong Kong Main Board-listed securities that can be invested through Southbound Stock Connect channels .
-
Sinopharm unanimously intends to acquire 70% equity of Guoda Disheng Pharmacy, etc.
Time of Update: 2021-07-23
On February 26, Sinopharm announced unanimously that the company’s board of directors agreed to its controlling subsidiary Guoda Pharmacy to acquire 70% of the shares of Guoda Disheng Pharmacy held b
-
Weijian Pharmaceutical and German Marksman once again signed a contract with Yabos to benefit domestic patients with hepatic encephalopathy
Time of Update: 2021-07-23
On February 26, 2021, Hong Kong Weijian Pharmaceutical Group and the German Max Pharmaceutical Factory announced a strategic cooperation .
The strategic cooperation between the two sides, marking the Victoria Health Medical German Maxwell's significant products Ya Division ® (ornithine aspartate) commercial interests in China .
